RESEARCH ARTICLE

The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples

Fangbin Song¹,²*, Hui Du¹,²*, Chun Wang¹,², Xia Huang¹,², Ruifang Wu¹,²*, CHIMUST team

¹ Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, PR China, ² Shenzhen Key Laboratory on Technology for Early Diagnosis of Major Gynecological Diseases, Shenzhen, Guangdong, PR China

☯ These authors contributed equally to this work.
¶ Membership of the Termite Genome Working Group is listed in the Acknowledgments.
* wurf100@126.com

Abstract

Background/Objective

Human papillomavirus (HPV) genotyping and cytology have been recommended for colposcopy triage, but it is unclear which combinations of high-risk HPV (hrHPV) types and cytology with various thresholds provide clinically useful information for the triage after primary HPV screening on self-collected samples.

Method

Chinese Multi-site Screening Trial (CHIMUST) database focused on self-collected samples was reviewed using the results of Cobas4800 HPV assay. Absolute risks of each genotype for cervical intraepithelial neoplasia 2 or worse/3 or worse (CIN2+/CIN3+) were calculated. Triage of atypical squamous cells of undetermined significance (ASCUS) or worse cytology was used as the comparator, and diagnostic accuracy for paired comparisons between algorithms was obtained using McNemar’s test.

Results

A total of 10,498 women were included, the overall prevalence of hrHPV, HPV16, HPV18, and Other hrHPV genotypes were 13.7%, 2.4%, 0.8%, and 10.5%, respectively. HPV16-positive women had the highest absolute risk among various genotypes for CIN2+/CIN3+ whether in normal or abnormal cytology (ASCUS or worse) and among all age groups. When compared with the comparator, combining HPV16 positivity and/or high-grade squamous intraepithelial lesion (HSIL) or worse yielded higher specificity (97.7% vs. 97.0%, p<0.0001), similar sensitivity (90.7% vs. 96.3%, p = 0.256) for detection of CIN3+, and a
Conclusions
Triage of HPV-positive women on self-collected samples by combining HPV16 or HPV16/18 genotyping with different thresholds of cytology could provide tradeoffs in sensitivity for detecting cervical lesions and colposcopy referral rates, and tailor management in various circumstances of clinical practice.

Introduction
Cervical cancer has caused estimated 311,365 deaths worldwide in 2018, with 90% occurring in developing countries[1]. Although three Human papillomavirus (HPV) vaccines have been approved successively in mainland China since 2016, none of them has been incorporated into the National Immunization Program yet. Accordingly, despite the effectiveness of vaccines, nearer-term impact will require delivery of cervical screening to older cohorts who will not benefit from HPV vaccination[2].

HPV test has been proved as a cost-effective primary screening method worldwide [3, 4], which could increase the coverage of screening via self-collected samples [5]. In low-resource areas without the infrastructure to support a cytology-based system, HPV testing can be done on self-collected samples, and this may offer opportunities to reach those who are reluctant to undergo gynecological examinations. Since self-collected sampling greatly reduces the physician workload for cervical cancer screening it can reduce cost and at the same time achieve better coverage in low-resource areas.

Most women find HPV self-sampling to be more convenient, less embarrassing, and less painful than clinician-sampling, but are concerned about test accuracy[6]. When used with high-risk HPV (hrHPV) assays that amplify the sample, such as polymerase chain reaction (PCR) assays, HPV testing on a self-collected sample is as sensitive as a clinician collected endocervical specimen for the detection of high-grade lesions [7, 8]. However, the management of HPV positive patients remains challenging due to the relatively low specificity of HPV testing in general[9].

Cytology and genotyping are the most common methods used for triage of HPV positive patients [9]. Cytological triage of a positive HPV test has been primarily proposed as an appropriate method of reducing colposcopy referrals. However, according to the Addressing the Need for Advanced HPV Diagnostics HPV Study (ATHENA trial), strategies that depended on cytology for triage of HPV-positive women decreased the sensitivity of HPV test[10]. Due to the differing risks associated with different genotypes [11, 12], partial types such as HPV16 and HPV18 are widely reported and used to guide clinical management[13]. Incorporating screening with HPV and triage of HPV-positive women by a combination of genotyping for HPV16/18 and cytology provided a good balance between maximizing sensitivity and specificity by limiting the number of colposcopies[10]. However, it is unclear what combinations of
genotyping for HPV16, or HPV16/18 with various thresholds of cytological grades provide clinically useful information for the triage after primary HPV screening.

In the present study, we reviewed the Chinese Multi-site Screening Trial (CHIMUST) database, and focused on self-collected samples, to explore the performance of HPV16 alone or HPV16/18 combined with different cytological cut-offs as methods of risk-stratification to triage patients after primary HPV screening.

Materials and methods

Subjects and study design

We reviewed the data from CHIMUST, a population-based study that was conducted in Beijing and 5 Provinces in China from Aug 2016 to Jan 2018 (The Trial Registration Number: ChiCTR-EOC-16008456). A total of 10,885 non-pregnant women, aged 29 to 60 years, with an intact uterus, without history of pelvic radiation, and without cervical cancer screening within 3 years were recruited. Briefly, CHIMUST is a primary HPV testing cervical cancer screening trial, all self-collected and clinician-collected samples were tested with the PCR-based hrHPV assays: Cobas4800 and SeqHPV (BGI, Shenzhen, China). Patients with HPV-positive results from any HPV assay on either self-collected or clinician-collected samples were randomly referred to colposcopy and biopsy. Cytology was used only for analysis and not for colposcopy referred requirements (S1 Fig). This study is a nested substudy of the CHUMUST trial, focusing on Cobas HPV assay on self-collected samples. Women with complete data on Cobas HPV on self-collected samples, cytology and histological results were analyzed. The CHIMUST protocol was approved by the Ethics Committee from the Peking University Shenzhen Hospital (PUSH), Shenzhen, China, as well as the current study (No. 2016001). All participants signed an informed consent before enrollment. Information that could identify individual participants was fully anonymized during or after data collection.

Self-sample collection and HPV DNA detection

All women who participated in the screening provided a self-collected vaginal sample. The participants were requested to place the sampling brush into the top of the vagina and then rotate it 3 times. After sampling, the brush with specimen was rubbed on a solid specimen processing (SSP) card, followed by placing it into a small bottle containing 6mL of PreservCyt® solution (Hologic, Marlborough, Mass. USA). Self-collected samples were prepared for the Cobas4800 assay (Roche) per the manufacturer’s instructions. Results from Cobas4800 testing are either HPV16 positive, HPV18 positive, other 12 types of hrHPV (Other hrHPV) positive, or HPV negative. Hierarchical typing results ranked as HPV16, HPV18, Other hrHPV, and negative.

Clinician-sample collection and liquid based cytology

After self-sampling, cervical exfoliated cell samples were obtained at the squamocolumnar junction of the cervix by prior-trained clinicians with a sampling brush which was subsequently placed into a 20mL PreservCyt® solution for testing on Cobas4800, SeqHPV, and cytology test (ThinPrep, Hologic). Cytology slides were interpreted by senior cytopathologists in PUSH according to the Bethesda classification system [14].

Colposcopy, biopsy and histological diagnoses

Patients with HPV positive results from any HPV assay in CHIMUST (Cobas4800, SeqHPV on either self-collected or clinician-collected samples) were called back for colposcopy and
biopsy. Colposcopy-directed biopsies were performed according to the Preventive Oncology International (POI) protocol [5]. Histological slides were analyzed by PUSH pathologists blind of any other testing results and the results were reported in 5 categories as negative, cervical intraepithelial neoplasia (CIN) 1, CIN 2, CIN 3, and cancers. In patients who had more than one tissue sample, the highest diagnosis was recorded. Women with atypical squamous cells of undetermined significance (ASCUS) or normal cytology and negative hrHPV results were considered to have a minimal risk of CIN and were classified as within normal limits [5].

Statistical analysis
Histologically confirmed CIN3 or worse (CIN3+) and CIN2 or worse (CIN2+) were used as the study endpoints. The absolute risks (ARs) of high-grade cervical disease were determined for different HPV types, and the respective 95% confidence intervals (CIs) for ARs were estimated by bootstrapping (1,000 times) [15]. Combinations of genotyping for HPV16, or HPV16/18 with different thresholds of cytological grades (≥ASCUS, low-grade squamous intraepithelial lesion or worse [≥LSIL], or high-grade squamous intraepithelial lesion or worse [≥HSIL]) were evaluated to identify potentially better algorithms for triage to immediate colposcopy in reference to the comparator, being cytology with a threshold of ASCUS [16]. Sensitivity, specificity, colposcopies referred rates, and number of colposcopies and cytology tests required to detect one case of CIN2+/CIN3+ were calculated. Exact p-values of diagnostic accuracy for paired comparisons between algorithms were obtained using McNemar’s test. Analyses were carried out using SPSS software 24.0 (IBM Company, Chicago, IL). All analyses were two-sided, and P values of <0.05 were considered statistically significant.

Results
Characteristics of study population
Out of 10,885 women offered self-sampling for hrHPV testing in CHUMUST, 58 women were excluded because invalid cytology, and 2 because invalid HPV, 265 because of not having histological results after HPV-positive results, 62 because HPV negative on all assays and cytology ≥ LSIL therefore without histopathology, leaving 10,498 cases available for analysis (Fig 1). The rate of compliance after colposcopy referral was 84.4% (1,437/1,702) in HPV-positive women. In the study population of total 10,498 women, the mean age was 44 years (range: 29–60 years). In addition, the majority had normal cytology (9782, 93.2%), 465 (4.4%) had ASCUS, 133 (1.3%) had LSIL or atypical glandular cell (AGC), 39 (0.4%) had atypical squamous cells cannot excluding high-grade lesions (ASC-H), and 79 (0.8%) had HSIL or worse cytology. Moreover, 5 women had a histological result of cervical cancer, 49 were diagnosed with CIN3 or adenocarcinoma in situ (AIS), 90 with CIN2, 159 with CIN1, and 10,212 with no CIN.

Prevalence of hrHPV on self-samples by age and cytology
Among the 10,498 women, the overall prevalence of hrHPV, HPV16, HPV18, and Other hrHPV genotypes were 13.7%, 2.4%, 0.8%, and 10.5%, respectively (Table 1). The overall prevalence of hrHPV positivity increased with age (P_trend<0.0001). Among women aged 50 to 60 years old, the prevalence of hrHPV positivity was highest of 15.4%, and the prevalence of HPV16 and/or 18 was highest of 3.7% among various groups (Table 1). Hierarchical typing results were significantly associated with cytological grades (P_trend<0.0001).
Risk stratification of HPV genotypes for CIN2+/CIN3+

The estimated ARs were dependent on hrHPV types, and HPV16 positivity achieved the highest ARs among various types for CIN2+/CIN3+ whether in normal or abnormal cytology (≥ASCUS) and in all age groups. The ARs for CIN2+ in women with hrHPV positivity/normal cytology, ranged from 1.6% (95% CI = 1.6–6.3%) for women positive of HPV18 to 9.7% (95%CI = 5.2–14.8%) for women positive of HPV16 (Table 2). The ARs for CIN3+ ranged from 1.3% (95%CI = 1.3–5.0%) in women positive of HPV18 to 14.1% (95%CI = 10.2–18.8%) in women positive of HPV16. ARs for various HPV genotypes stratified by age and cytology were shown in Table 2.

Fig 1. Selection of the study population. NILM, negative for intraepithelial lesion or malignancy; ASCUS, atypical squamous cells of undetermined significance.

https://doi.org/10.1371/journal.pone.0234518.g001
Prevalence of histological grades by triage tests

Table 3 presented the distribution of histological outcomes according to cytology grades and genotypes. Histological results were available for 1,437 of the hrHPV-positive women. The majority of these women had normal cytology (74.3%) and normal histological results (79.6%). Moreover, prevalence of cytology abnormality (ASCUS, LSIL, and HSIL), genotyping for HPV16, and genotyping for HPV16/18 were increased with the aggravation of the histological grades (All \( P_{\text{trend}} < 0.0001 \)).

Table 1. Prevalence of hrHPV and genotypes on self-samples by age and cytology.

| Characteristics | Total | hrHPV results (%) | Chi-square (p-value) |
|-----------------|-------|-------------------|----------------------|
|                 |       | hrHPV+ | HPV16+ | HPV18+ | Other hrHPV+ |       |
| Age: Mean ± SD (Y) | 44 ± 7.5 | 13.7 | 2.4 | 0.8 | 10.5 | 1.2 (p = 0.267) |
| Overall | 10498 | 11.2 | 2.3 | 0.6 | 8.3 | 3310 |
| 29–39 | 4396 | 14.5 | 2.5 | 0.6 | 11.4 | 2792 |
| 50–60 | 79 | 15.4 | 2.5 | 1.2 | 11.7 | 9782 |
| NILM | 465 | 10.9 | 1.6 | 0.7 | 8.7 | NILM |
| ASCUS | 172 | 82.6 | 18.0 | 2.9 | 61.6 | ASCUS |
| LSIL/ASC-H/AGC | 79 | 91.1 | 49.4 | 3.8 | 38.0 | LSIL/ASC-H/AGC |

NILM, no intraepithelial lesion and malignant cells; ASCUS, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; AGC, atypical glandular cell; ASC-H, atypical squamous cells, cannot excluding HSIL; SD, standard deviation; hrHPV, high-risk human papillomavirus

https://doi.org/10.1371/journal.pone.0234518.t001

Prevalence of histological grades by triage tests

Table 3 presented the distribution of histological outcomes according to cytology grades and genotypes. Histological results were available for 1,437 of the hrHPV-positive women. The majority of these women had normal cytology (74.3%) and normal histological results (79.6%). Moreover, prevalence of cytology abnormality (\( \geq \text{ASCUS} \), \( \geq \text{LSIL} \), and \( \geq \text{HSIL} \)), genotyping for HPV16, and genotyping for HPV16/18 were increased with the aggravation of the histological grades (All \( P_{\text{trend}} < 0.0001 \)).

Table 2. Impact of hrHPV types on estimated absolute risk of CIN2+/CIN3+ (%).

| Factors | Overall | \( 29–39 \) | \( 40–49 \) | \( 50–60 \) | NILM | \( \geq \text{ASCUS} \) |
|---------|---------|----------|----------|----------|------|-------------|
| CIN2+   |         |          |          |          |      |             |
| hrHPV+  | 3.6 (2.6–4.7) | 3.2 (1.4–5.4) | 4.2 (2.8–6.0) | 3.0 (1.6–4.7) | NA | 14.1 (10.8–17.8) |
| HPV16+and/or 18+ | 11.0 (7.8–14.6) | 9.3 (4.1–15.5) | 15.6 (9.6–22.2) | 6.8 (1.9–12.6) | NA | 31.9 (23.3–40.5) |
| HPV18+  | 1.3 (1.3–5.0) | NA | 3.8 (3.8–13.1) | NA | NA | 6.3 (6.3–24.7) |
| Other hrHPV+ | 1.4 (0.7–2.1) | 1.1 (0.4–2.6) | 1.2 (0.4–2.2) | 1.8 (0.6–3.4) | NA | 5.9 (3.1–9.1) |

Absolute risk (%) is the number of subjects with disease /number of subjects with positive test results; NILM, no intraepithelial lesion and malignant cells; ASCUS, atypical squamous cells of undetermined significance; CIN2+/CIN3+, cervical intraepithelial neoplasia 2 or worse/ 3 or worse; NA, not applicable; hrHPV, high-risk human papillomavirus; NA, not available

https://doi.org/10.1371/journal.pone.0234518.t002
Different triage strategies for the detection of CIN3+ (Table 4) and CIN2+ (Table 5)

We investigated various combinations of genotyping for HPV16, or HPV16/18 with different thresholds of cytology for the triage of HPV-positive women. The characteristics of all 18 strategies (HPV alone and 17 triage strategies) for detecting CIN3+ lesions are detailed in Table 4 and that for detecting CIN2+ lesions are given in Table 5. Triage with cytology testing with an ASCUS threshold (Strategy 2), was used as the comparator, showed a sensitivity of 70.1% (95% CI = 62.0–77.5%), a specificity of 97.4% (95% CI = 97.1–97.7%) for CIN2+. Moreover, the referral rate was 3.5%, and 3.7 colposcopies were needed to find 1 CIN2+.

Notably, of the 17 triage strategies, the one with positivity for HPV16 and/or ASCUS cytology (Strategy 7) and the one with positivity for (HPV16 and/or HPV18) and/or ASCUS cytology (Strategy 13) achieved favorable sensitivity compared with strategy 2 (both 96.3% vs. 96.3% for CIN3+, p = 1.000; 80.6% and 81.3% vs. 70.1% respectively for CIN2+, p <0.001), these algorithms would reduce the colposcopy referral rate to 5.0% and 5.6%, respectively, compared with 13.7% of that for HPV alone.

Furthermore, HPV16 positivity and/or ≥HSIL (Strategy 11) showed an improved specificity of 97.5% (95%CI = 97.2–97.8) at a similar sensitivity of 92.6% (95% CI = 82.1–97.9) for CIN3+ relative to the comparator, and achieved a referral rate of 2.9% and 6.1 colposcopies to detect one CIN3+. These findings were replicated for the endpoint of CIN2+. In addition, HPV16 positivity and/or ≥LSIL cytology (Strategy 9) showed a similar specificity and a comparable sensitivity for detecting CIN2+/CIN3+ to the comparator. However, (HPV16 and/or 18 positivity) and/or ≥LSIL as triage (Strategy 15) revealed comparable sensitivities and worse specificities for detecting CIN2+/CIN3+ compared with the comparator.

Strategy 3 raised the threshold to LSIL, yielding a favorable specificity and a comparable sensitivity for detection of CIN3+ to the comparator, but leading to a worse sensitivity for detection of CIN2+ with misdiagnosis of more high-grade diseases. None of the other strategies showed improvement in specificity without a decreased sensitivity for the detection of CIN2+/CIN3+ as compared to the comparator. Among them, HPV16 alone or HPV16/18
Table 4. Performance of different triage algorithms of HPV positive women for CIN3+ detection.

| Triage strategies after primary hrHPV screening | SEN, % | SPE, % | PPV, % | NPV, % | Colposcopy referral rate, % | Cytology test rate % | Colposcopies to detect 1 CIN3+ |
|-----------------------------------------------|--------|--------|--------|--------|-----------------------------|----------------------|-----------------------------|
| 1. None (all HPV positivity to colposcopy)     | 96.3   | 86.7   | 3.6    | 100.0  | 13.7                        | 0.0                  | 27.63                       |
| 2. ≥ASCUS (comparator)                        | 96.3   | 97.0   | 14.1   | 100.0  | 3.5                         | 13.7                 | 7.1                         |
| 3. ≥LSIL                                      | 92.6   | 98.1   | 19.9   | 100.0  | 2.4                         | 13.7                 | 5.0                         |
| 4. ≥HSIL                                      | 75.9   | 99.6   | 51.9   | 99.9   | 0.8                         | 13.7                 | 1.9                         |
| 5. HPV16+                                     | 66.7   | 97.9   | 36.0   | 99.8   | 3.8                         | 11.3                 | 2.8                         |
| 6. HPV16+ and/or 18+                          | 94.4   | 96.7   | 12.8   | 100.0  | 3.8                         | 11.3                 | 7.8                         |
| 7. HPV16+ and/or ≥ASCUS                       | 96.3   | 95.5   | 9.9    | 100.0  | 5.0                         | 11.3                 | 5.9                         |
| 8. HPV16+ and/or LSIL                         | 94.4   | 96.7   | 0.0    | 100.0  | 7.1                         | 11.3                 | 1.5                         |
| 9. HPV16+ and/or HSIL                         | 90.7   | 97.7   | 17.0   | 100.0  | 2.7                         | 11.3                 | 5.9                         |
| 10. HPV16+ and ≥LSIL                         | 48.1   | 99.9   | 66.7   | 99.7   | 0.4                         | 11.3                 | 1.5                         |
| 11. HPV16+ and/or ≥HSIL                       | 70.1   | 97.4   | 27.3   | 99.2   | 5.6                         | 10.5                 | 11.3                       |
| 12. HPV16+ and ≥HSIL                         | 61.1   | 98.4   | 35.1   | 99.5   | 2.4                         | 10.5                 | 3.1                         |
| 13. (HPV16+ and/or 18+) and/or ≥ASCUS         | 85.3   | 94.9   | 8.8    | 100.0  | 5.6                         | 10.5                 | 11.3                       |
| 14. (HPV16+ and/or 18+) and ≥ASCUS            | 68.5   | 99.2   | 31.9   | 99.8   | 1.1                         | 10.5                 | 3.1                         |
| 15. (HPV16+ and/or 18+) and/or ≥LSIL          | 94.4   | 96.0   | 10.8   | 100.0  | 4.5                         | 10.5                 | 9.2                         |
| 16. (HPV16+ and/or 18+) and ≥LSIL             | 63.0   | 99.6   | 43.6   | 99.8   | 0.7                         | 10.5                 | 2.3                         |
| 17. (HPV16+ and/or 18+) and/or ≥HSIL          | 90.7   | 97.0   | 13.4   | 100.0  | 3.5                         | 10.5                 | 7.5                         |
| 18. (HPV16+ and/or 18+) and ≥HSIL             | 50.0   | 99.9   | 64.3   | 99.7   | 0.4                         | 10.5                 | 1.6                         |

Bold value indicates that the value is significantly different from that of the comparator (p<0.01). SEN, sensitivity; SPE, specificity; ASCUS, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; CIN3+, cervical intraepithelial neoplasia 3 or worse; HPV, human papillomavirus; PPV, positive predictive value; NPV, negative predictive value.

https://doi.org/10.1371/journal.pone.0234518.t004

Table 5. Performance of different triage algorithms of HPV positive women for CIN2+ detection.

| Triage algorithms after primary hrHPV screening | SEN, % | SPE, % | PPV, % | NPV, % | Colposcopy referral rate, % | Cytology test rate % | Colposcopies to detect 1 CIN2+ |
|------------------------------------------------|--------|--------|--------|--------|-----------------------------|----------------------|-----------------------------|
| 1. None (all HPV positivity to colposcopy)     | 93.80  | 87.4   | 9.4    | 99.9   | 13.7                        | 0.0                  | 10.6                        |
| 2. ≥ASCUS (comparator)                        | 70.1   | 97.4   | 27.3   | 99.2   | 3.5                         | 13.7                 | 3.7                         |
| 3. ≥LSIL                                      | 61.1   | 98.4   | 35.1   | 99.5   | 2.4                         | 13.7                 | 2.9                         |
| 4. ≥HSIL                                      | 43.1   | 99.8   | 78.5   | 99.2   | 0.8                         | 13.7                 | 1.3                         |
| 5. HPV16+                                     | 46.5   | 98.2   | 26.3   | 99.2   | 2.4                         | 0.0                  | 3.8                         |
| 6. HPV16+ and/or 18+                          | 49.3   | 97.5   | 21.2   | 99.3   | 3.2                         | 0.0                  | 4.7                         |
| 7. HPV16+ and/or ≥ASCUS                       | 80.6   | 96.0   | 22.1   | 99.7   | 5.0                         | 11.3                 | 4.5                         |
| 8. HPV16+ and ≥ASCUS                          | 36.1   | 99.5   | 52.0   | 99.1   | 1.0                         | 11.3                 | 1.9                         |
| 9. HPV16+ and/or ≥LSIL                        | 74.3   | 97.2   | 26.8   | 99.6   | 3.8                         | 11.3                 | 3.7                         |
| 10. HPV16+ and ≥LSIL                         | 31.3   | 99.8   | 64.3   | 99.1   | 0.7                         | 11.3                 | 1.6                         |
| 11. HPV16+ and/or ≥HSIL                       | 64.6   | 98.1   | 32.3   | 99.5   | 2.7                         | 11.3                 | 3.1                         |
| 12. HPV16+ and ≥HSIL                         | 22.9   | 99.9   | 84.6   | 98.9   | 0.4                         | 11.3                 | 1.2                         |
| 13. (HPV16+ and/or 18+) and/or ≥ASCUS         | 81.3   | 95.4   | 19.9   | 99.7   | 5.6                         | 10.5                 | 5.0                         |
| 14. (HPV16+ and/or 18+) and ≥ASCUS            | 38.2   | 99.4   | 47.4   | 99.1   | 1.1                         | 10.5                 | 2.1                         |
| 15. (HPV16+ and/or 18+) and/or ≥LSIL          | 75.7   | 96.5   | 23.1   | 99.7   | 4.5                         | 10.5                 | 4.3                         |
| 16. (HPV16+ and/or 18+) and ≥LSIL             | 32.6   | 99.7   | 60.3   | 99.1   | 0.7                         | 10.5                 | 1.7                         |
| 17. (HPV16+ and/or 18+) and/or ≥HSIL          | 66.0   | 97.4   | 26.0   | 99.5   | 3.5                         | 10.5                 | 3.8                         |
| 18. (HPV16+ and/or 18+) and ≥HSIL             | 24.3   | 99.9   | 83.3   | 99.0   | 0.4                         | 10.5                 | 1.2                         |

Bold value indicates that the value is significantly different from that of the comparator (p<0.01). SEN, sensitivity; SPE, specificity; ASCUS, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; CIN2+, cervical intraepithelial neoplasia 2 or worse; HPV, human papillomavirus. PPV, positive predictive value; NPV, negative predictive value.

https://doi.org/10.1371/journal.pone.0234518.t005

https://doi.org/10.1371/journal.pone.0234518.t005
positivity, yielded lower sensitivities for the detection of CIN3+ than the comparator (66.7% and 68.5% vs. 96.3% respectively, \( p < 0.0001 \)).

**Discussion**

In the current study, the prevalence rate of hrHPV was 13.7% on self-collected samples. The high prevalence of hrHPV not only leads to unnecessary colposcopy or follow-up burden\[9\], but also might add to the mental burden of the HPV-positive women\[17\]. However, in HPV-based screening programs, there is still no consensus on the optimal management of HPV-positive women to maximize disease detection and minimize colposcopy rates \[18, 19\].

Risk stratification has important implications for the personalized risk management of HPV positive women. For instance, optimizing triage strategies to decide whether referring the patients to immediate colposcopy or follow up\[9\]. Even after a woman is referred to colposcopy, knowing risk estimates might guide the biopsies taken\[20\]. In this study, HPV16 infection conferred the highest absolute risks among all genotypes for CIN2+/CIN3+ in overall population and all age groups, which is in consistent with the results of ATHENA trial\[21\]. However, although the lower overall absolute risk of HPV18 than Other hrHPV in this study, HPV18 is of particular significance due to its association with difficult-to-detect glandular lesions and cancers\[22\]. Therefore, HPV16 alone or combined with HPV18 could be considered as a maker to personalize triage plans after primary HPV screening\[11\].

Morphological cytology and molecular HPV genotypes are two most common triages used in clinical practice\[23\]. Different triage methods compared in our study were similar with those from the ATHENA trial conducted in America\[21\] and PROHTTECT-3B study in the Netherlands by offering self-sampling\[21, 24\]. The overall and type-specific HPV prevalence among different populations vary greatly by geographic region, ethnic diversity and level of income\[25\]. For example, a relatively high contribution of HPV58 to cervical cancer in East Asia has been reported \[16\]. In light of these facts, it is questionable whether similar strategies would be effective in the Chinese population. To our knowledge, there was little study to evaluate the performance of such triage strategies on HPV-positive self-samples in China, particularly large population-based studies. Accordingly, among 10,498 screened women, we assessed the performance of 17 sequential triage algorithms based on HPV16/18 or HPV16 combined with different thresholds of cytology, for the detection of cervical diseases in order to extend the available options for management of hrHPV positive women on self-collected samples since no single strategy that is suitable across all circumstances.

Although several strategies such as dual staining and methylation makers are under consideration in some countries, “cytology ≥ ASCUS” is currently one of the most common triage strategies in clinical practice\[9, 13\], and was performed as the comparator. Similar with prior studies\[21, 24\], on the basis of our findings, HPV16 (not HPV16/18) combined with a raised threshold of abnormal cytology (≥HSIL) achieve a good performance with favorable specificity and comparable sensitivity versus the comparator. As a result, the colposcopy referral rate decreases from 3.5% to 2.7%; and instead of 7.1 colposcopies, only 5.9 colposcopies needed for detection of one CIN3+. Consequently, with less requirement for colposcopy referral and cytology testing compared with the comparator, this strategy may be more suitable for young and fertile women for whom overtreatment may be harmful in future fertility and pregnancies, while less aggressive detection and management of high-grade lesions may be needed \[26\]. In addition, there might be a need to reduce the colposcopy rate because of risk of overdiagnosis, high costs, and unnecessary anxiety for the women involved. Furthermore, a watchful waiting policy could be considered for a case of CIN2 since a significant proportion of lesions will regress spontaneously, particularly in young and fertile women\[24\].
The medical resources required and health care professionals, as well as healthy perceptions of women, are key factors that should be addressed to ensure effective cervical screening programs [27]. Of the 17 triage strategies, the one with positivity for HPV16 and/or ≥ASCUS and the one with positivity for (HPV16 and/or HPV18) and/or ≥ASCUS achieved favorable sensitivity and might reduce secondly loss to follow-up rate compared with the comparator; although with a little lower specificity compared with the comparator, these algorithms would reduce the referral rate to 5.0% and 5.6% respectively compared with 13.7% of that for HPV alone, and require less cytological test compare with the comparator. Since women in low-resource areas are less likely to contact with health care services, early detection of cervical cancer and precancer will generally produce a better outcome for women’s overall health as well as public health in the long run [27]. Moreover, screening algorithms with low sensitivity require frequent repetitions of cervical screening, which pose logistical barriers to adherence to follow-up advices for women in rural areas as well as inequity in access to services [27]. Accordingly, when there is a clinical need to use a test with high potential sensitivity, such as women in low-resource settings where access to appropriate follow-up is challenging and women with serious stress or anxiety on HPV infection, these two strategies (HPV16 and/or ≥ASCUS; HPV16/18 and/or ≥ASCUS) may be appropriate alternatives to achieve the goal of preventing cervical cancer. They targeted a balance between achieving favorable sensitivity relative to the comparator and reducing substantial colposcopy referral compared to HPV testing alone.

Of the 17 triage strategies, combining HPV16 positivity and/or LSIL or worse achieved similar specificity and comparable sensitivity for detection of CIN2+/CIN3+ to the comparator. However, a prior study [24] showed that HPV16 and/or LSIL cytology as triage achieve favorable specificity and comparable sensitivity. Additionally, although the high risk of HPV16/18 contributed to cervical cancer, HPV16/18 couldn’t be used as a sole triage since its low sensitivity, which is consistent with prior studies [21, 24].

One limitation of this substudy is that there might be a verification bias since not all the women underwent biopsy, for instance, some women negative of HPV didn’t meet the requirements of colposcopy referring. However, several HPV assays including cobas4800 and Seq HPV either on self-collected or clinician-collected samples were performed, and all the hrHPV-positive women were suggested to be referred to colposcopy-guided biopsy according to standard POI protocol as well as a high compliance rate of colposcopy referral in HPV-positive women [5], which reduces misdiagnosis, hence the majority of disease was detected in the study population. Moreover, all the slides were reviewed by the senior pathologists in PUSH and subjected to quality control, which makes the results more accuracy and comparable. A major strength of the current study is that it is derived from CHUMUST with a large sample size of natural population from six settings in China, which reflects the diverse demography of Chinese population. Therefore, the findings above may be applicable to routine practice and generalizable to populations with similar characteristics.

Efficient cancer prevention is based on detecting and treating precancers before they become cancer. Implementing this effectively and still avoiding overtreatment should be the primary goal of cervical cancer screening [9]. In several studies, the approach of HPV primary screening and reflex with genotyping and cytology, despite the high colposcopy referral rate, was still found to be the most cost-effective relative to other strategies, including cytology-based screening, co-testing of HPV and cytology, and HPV primary screening with reflex to cytology [10, 21, 24, 27]. There is no single screening modality that could cover all clinical needs; on the basis of our findings and prior studies [24, 28], combination HPV16 or HPV18, with different thresholds of cytology offers personalized management for HPV-positive women in clinical practice.
In conclusion, the study revealed that combinations of HPV16 and the threshold HSIL improves the colposcopy referral rate, cytology testing rate and the specificity for detecting CIN3+ lesions while maintaining adequate sensitivity compared with the triage of cytology ≥ ASCUS, thus could be used as a preferred screening strategy for young and fertile women. Combinations of HPV16 or HPV16/18 with ASCUS or worse could improve sensitivity and cytology rate compared with triage of cytology ≥ ASCUS, and reduce substantial colposcopy referrals compared with HPV testing alone. Sequential triage algorithms that combinations of HPV16 or HPV16/18 and different thresholds of cytology provide guidance for individualized management of HPV-positive women in clinical practice, and offer practical alternatives for organizing HPV-based screening programs, particularly in low-resource areas.

Supporting information

S1 File.
(XLSX)

S1 Fig.
(TIF)

Acknowledgments

We thank Jerome L. Belinson for his important advice on editing a draft of this manuscript, and Xinfeng Qu for his kind help for revising this paper.

CHUMUST team: Lead author, Ruifang Wu, E-mail: wurf100@126.com, Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital, and Shenzhen Key Laboratory on Technology for Early Diagnosis of Major Gynecological Diseases, PR China. Jerome L. Belinson, Preventive Oncology International, Inc. and the Cleveland Clinic, Cleveland, USA. Lihui Wei, Department of Obstetrics and Gynecology, Peking University People’s Hospital, PR China. Yan Liu, The Northern Division of Huashan Hospital Affiliated to Fudan University, PR China. Xianzhi Duan, Hua Jin, Mongolia Wushenqi People’s Hospital, PR China. Wei Zhang, Zhongnan Hospital Affiliated to Wuhan University. Bin Shi, The Second Hospital of Hebei Medical University, PR China. Bin Yang, The Cleveland Clinic, Cleveland, USA. Hui Du, Ruizhen Li, Guixiang Wang, Lijie Zhang, Chun Wang, Hongxue Luo, Xia Huang, Danhong Huang, Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital, and Shenzhen Key Laboratory on Technology for Early Diagnosis of Major Gynecological Diseases, PR China. Xinfeng Qu, Sanming Project of Medicine in Shenzhen, Peking University Shenzhen Hospital, PR China. Jing Mei, Medical Records and Statistics Room, Peking University Shenzhen Hospital, PR China.

Author Contributions

Conceptualization: Fangbin Song, Ruifang Wu.
Data curation: Hui Du, Chun Wang, Xia Huang.
Formal analysis: Fangbin Song, Hui Du.
Investigation: Hui Du, Chun Wang, Xia Huang.
Project administration: Xia Huang, Ruifang Wu.
Resources: Ruifang Wu.
Writing – original draft: Fangbin Song.
Writing – review & editing: Ruifang Wu.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68(6):394–424. https://doi.org/10.3322/caac.21492 PMID: 30207593

2. Simms KT, Steinberg J, Caruana M, Smith MA, Lew JB, Soerjomataram I et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study. Lancet Oncol. 2019, 20(3):394–407. https://doi.org/10.1016/S1470-2045(18)30836-2 PMID: 30795950

3. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014, 383(9916):524–532. https://doi.org/10.1016/S0140-6736(13)62218-7 PMID: 24192252

4. Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aïделburger P W J, Mitterdorf T et al. Cost-effectiveness of primary HPV screening for cervical cancer in Germany—a decision analysis. Eur J Cancer. 2011, 47(11):1633–1646. https://doi.org/10.1016/j.ejca.2011.03.006 PMID: 21482103

5. Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001, 83(2):439–444. https://doi.org/10.1006/gyno.2001.6370 PMID: 11606114

6. Ketelaars PJW, Bosgraaf RP, Siebers AG, Massuger LFAG, van der Linden JC, Wauters CAP et al. High-risk human papillomavirus detection in self-sampling compared to physician-taken smear in a responder population of the Dutch cervical screening: Results of the VERA study. Prev Med. 2017, 101:96–101. https://doi.org/10.1016/j.ypmed.2017.05.021 PMID: 28579497

7. Arbyn M, Verduoord F, Snijders PJF, Verhoef VMJ, Suonio E, Dillner L et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. The Lancet Oncology. 2014, 15(2):172–183. https://doi.org/10.1016/s1470-2045(13)70570-9 PMID: 24433684

8. Arbyn M, Smith SB, Temjin S, Sultana F, Castle P, Collaboration on S-S et al. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018, 363:k4823. https://doi.org/10.1136/bmj.k4823 PMID: 30518635

9. Cuschieri K, Ronco G, Lorincz A, Smith L, Ogilvie G, Mirabello L et al. Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs. Int J Cancer. 2018, 143(4):735–745. https://doi.org/10.1002/ijc.31261 PMID: 29341110

10. Cox J, Castle PE, Behrens CM S A, Wright TC, Cuzick J, Athena HPV Study Group. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013, 208(3):184.e181–e111. https://doi.org/10.1016/j.ajog.2012.11.020 PMID: 23174289

11. Adcock R, Cuzick J, Hunt WC, McDonald RM, Wheeler CM. Role of HPV genotype, multiple infections and viral load on the risk of high-grade cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2019, 28(11):1816–1824. https://doi.org/10.1158/1055-9965.EPI-19-0239 PMID: 31488417

12. Monsonego J, Cox JT, Behrens C, Sandri M, Franco EL, Yap PS et al. Prevalence of high-risk human papillomavirus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial. Gynecol Oncol. 2015, 137(1):47–54. https://doi.org/10.1016/j.ygyno.2015.01.551 PMID: 25667973

13. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015, 136(2):178–182. https://doi.org/10.1016/j.ygyno.2014.12.022 PMID: 25579107

14. Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M et al. The 2001 Bethesda System: Terminology for reporting results of cervical cytology. JAMA. 2002, 287(16):2114–2119. https://doi.org/10.1001/jama.287.16.2114 PMID: 11966386

15. Lahiri SN. Bootstrap methods: a practitioner’s guide. Journal of Statistical Planning and Inference 2000, 91(1):171–172. https://doi.org/10.1016/S0378-3758(00)00132-4

16. Chan PK, Cheung TH, Li WH, Yu MY, Chan MY, Yim SF et al. Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China. Int J Cancer. 2012, 131(3):692–705. https://doi.org/10.1002/ijc.26404 PMID: 21976212
17. Dodd RH, Mac O, Brotherton JML, Cvejic E, McCaffery KJ. Levels of anxiety and distress following receipt of positive screening tests in Australia’s HPV-based cervical screening programme: a cross-sectional survey. Sex Transm Infect. 2020. https://doi.org/10.1136/sextrans-2019-054290 PMID: 32001660

18. Dong L, Wang MZ, Zhao XL, Feng RM, Hu SY, Zhang Q et al. Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study. Gynecol Oncol. 2018, 148(1):103–110. https://doi.org/10.1016/j.ygyno.2017.11.016 PMID: 29169614

19. Stoler MH, Baker E, Boyle S, Aslam S, Ridder R, Huh WK et al. Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology—retrospective insights from ATHENA. Int J Cancer. 2019. https://doi.org/10.1002/ijc.32669 PMID: 31490545

20. Wentzensen N, Walker JL, Gold MA, Smith KM, Zuna RE, Mathews C et al. Multiple Biopsies and Detection of Cervical Cancer Precursors at Colposcopy. J Clin Oncol. 2015, 33(1):83–89. https://doi.org/10.1200/jco.2014.55.9948 PMID: 25422481

21. Castle Philip E, Stoler Mark H, Wright Thomas C Jr, Sharma Abha, Wright Teresa L, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV 16 or HPV 18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011, 12(9):880–890. https://doi.org/10.1016/S1470-2045(11)70188-7 PMID: 21865084

22. Schiffman M, Burk RD, Boyle S, Raine-Bennett T, Katki HA, Gage JC et al. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. J Clin Microbiol. 2015, 53(1):52–59. https://doi.org/10.1128/JCM.02116-14 PMID: 25339398

23. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasigam SL, Cain J et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012, 62(3):147–172. https://doi.org/10.3322/caac.21139 PMID: 22422631

24. Ebisch RM, de Kuyper-de Ridder GM, Bosgraaf RP, Massuger LF, IntHout J, Verhoef VM et al. The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples. Int J Cancer. 2016, 139(3):691–699. https://doi.org/10.1002/ijc.30090 PMID: 26991464

25. Bao H, Zhang L, Wang L, Zhang M, Zhao Z, Fang L et al. Significant variations in the cervical cancer screening rate in China by individual-level and geographical measures of socioeconomic status: a multi-level model analysis of a nationally representative survey dataset. Cancer Med. 2018, 7(5):2089–2100. https://doi.org/10.1002/cam4.1321 PMID: 29573569

26. Athanasiou A, Veroniki AA, Efthimiou O, Kalliala I, Naci H, Bowden S et al. Comparative fertility and pregnancy outcomes after local treatment for cervical intraepithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and network meta-analysis from the CIRCLE group. BMJ Open. 2019, 9(10):e028009. https://doi.org/10.1136/bmjopen-2018-028009 PMID: 31636110

27. Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazzcano-Ponce E, Franco EL et al. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico. JAMA Netw Open. 2019, 2(11):e1915781. https://doi.org/10.1001/jamanetworkopen.2019.15781 PMID: 31747033

28. Chatzistamatiou K, Mosyiadis T, Moschaki V, Panteleris N, Agorastos T. Comparison of cytology, HPV DNA testing and HPV 16/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening. Gynecol Oncol. 2016, 142(1):120–127. https://doi.org/10.1016/j.ygyno.2016.04.027 PMID: 27126005